Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.p.a.

Steven W Ludmerer

Joseph P Vacca

John A McCauley

Nigel J Liverton

David Brian Olsen

Michael T Rudd

M Katharine Holloway

Hao Wu

Craig Alan Coburn

Kun Liu

Jian Zhu

Osvaldo A Flores

Bin Zhong

Donald J Graham

Robert L LaFemina

Kathrin Ute Jansen

Richard Soll

Charles J McIntyre

George E Mark, Iii

William L McClements

Xin-Min Wang

Amy L Simcoe

Diana Benincasa

Jessica C Ling

Bin Hu

Fei Sun

Gregory Franklin Hollis

Xinghai Wang

Mingwei Zheng

Maura Pizzuti

Cinzia Traboni

Richard Soil

Chengren Zhang

Man Yan

John A Mccauley

Charles J Mcintyre

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. 

Inhibitors of hepatitis C virus replication

The present invention features methods for enhancing the ability of a genotype 2b NS5B sequence to function in a replicon, for producing replicons containing a functional genotype 2b NS5B, and for using replicons to measure the ability of a compound to affect HCV replication that is sustained with the genotype 2b polymerase. Also featured is a genotype 1b NS4B adaptive mutation. The ability to produce replicons containing a functional genotype 2b NS5B is illustrated by the production of chimeric replicons based on HCV genotype 1b where substantially all the NS5B sequence is replaced with a genotype 2b NS5B.

HCV replicons containing NS5B from genotype 2B

The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. 

HCV NS3 protease inhibitors

The present invention features NS5B polypeptides from different clinically important HCV genotypes. The polypeptides can be used individually, or as part of a panel of RNA-dependent RNA polymerases, to evaluate the effectiveness of a compound to inhibit NS5B activity.

HCV RNA-dependent RNA polymerase

The invention is a series of synthetic virus-like particles comprising a heterologous conformational epitope useful in the characterization of human papillomavirus infection, and useful to vaccinate individual for protection against HPV 6 and HPV 11 infections, and assays employing the synthetic virus-like particles.

Synthetic virus-like particles with heterologous epitopes

Synthetic virus like particles with heterologous epitopes

A series of synthetic virus-like particles useful in the characterization of human papillomavirus type 16 (HPV16) infection and assays employing the synthetic particles are provided.

Synthetic HPV 16 virus-like particles

The invention is a series of synthetic virus-like particles useful in the characterization of human papillomavirus infection and assays employing the synthetic virus-like particles.

Synthetic HPV16 virus-like particles

The present invention is a series of synthetic virus-like particles useful in the characterization of human papillomavirus infection and assays employing the synthetic virus-like particles.

Synthetic HPV11 virus-like particles

Growing community of inventors

North Wales, PA, United States of America

Steven W Ludmerer